Retatrutide Peptide Research: Triple Receptor Agonism, Metabolic Mechanisms, and Preclinical Evidence

Retatrutide (LY3437943) is a single-peptide agonist of the GLP-1, GIP and glucagon receptors, and retatrutide peptide research is watched closely because adding glucagon receptor activity to incretin agonism raises energy expenditure as well as lowering intake. In the 48-week phase 2 obesity trial, the least-squares mean change in body weight in the highest maintenance group was -24.2 percent against -2.1 percent for placebo (Jastreboff et al., New England Journal of Medicine, 2023, 389:514-526). The mechanism, the preclinical evidence and the published clinical proof-of-concept data are summarized below, with the papers that support each statement.

Retatrutide differs from single-target GLP-1 receptor agonists such as semaglutide and from dual GIP and GLP-1 receptor agonists such as tirzepatide in one respect: it engages the glucagon receptor as well. That third activity is the reason the compound exists, and it is also the source of the design constraints described below.

Molecular Structure and Receptor Profile

Retatrutide is a 39-residue peptide built on a GIP-derived sequence and carrying a C20 fatty diacid on a lysine side chain, the same albumin-binding strategy used for semaglutide and tirzepatide, which is what gives it a once-weekly pharmacokinetic profile. Coskun and colleagues, who reported the discovery, describe its in vitro pharmacology as balanced activity at the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R) with greater activity at the GIP receptor (GIPR) (Coskun et al., Cell Metabolism, 2022, 34:1234-1247). The paper’s title, “from discovery to clinical proof of concept,” is accurate: it carries the molecule from receptor assays through obese-mouse studies to a first-in-human phase 1 study in one report. Absolute potency values at each receptor are given in the paper’s figures and supplement rather than its abstract, and this article does not reproduce them; the qualitative ranking, GIPR above GLP-1R and GCGR, is the published summary.

Why the Glucagon Receptor Component Matters

Glucagon was long regarded only as insulin’s counter-regulatory partner, raising blood glucose through hepatic glycogenolysis and gluconeogenesis. Habegger and colleagues review the evidence that glucagon also stimulates energy expenditure, lowers lipids and reduces food intake, which is what makes it a candidate component of an anti-obesity agent rather than a liability (Habegger et al., Nature Reviews Endocrinology, 2010, 6:689-697). The proof that the two activities can be combined in one molecule came from Day and colleagues, whose glucagon and GLP-1 co-agonist normalized adiposity and glucose tolerance in diet-induced obese mice with weight loss arising from both decreased food intake and increased energy expenditure (Day et al., Nature Chemical Biology, 2009, 5:749-757). Pocai and colleagues reached the same conclusion with a different dual agonist matched for GLP-1R potency and pharmacokinetics against a GLP-1R-selective control, finding superior weight loss and lipid lowering, increased fatty acid oxidation and reduced hepatic steatosis, and showing in receptor knockout mice that the anti-obesity effect required both receptors (Pocai et al., Diabetes, 2009, 58:2258-2266).

The triple-agonist concept itself predates retatrutide. Finan and colleagues reported a rationally designed monomeric peptide with balanced, supraphysiological potency at all three receptors and used genetic knockout, pharmacological blockade and selective chemical knockout to assign the contribution of each: glucagon action increased energy expenditure, GLP-1 action reduced caloric intake and improved glucose control, and GIP action potentiated the incretin effect and buffered the diabetogenic tendency of the glucagon component (Finan et al., Nature Medicine, 2015, 21:27-36). That division of labour is the framework in which retatrutide’s data are read: GCGR agonism is the lever on energy expenditure, and GIPR and GLP-1R agonism are what keep glucose control intact while it is pulled.

Preclinical Metabolic Research Findings

In obese mice, Coskun and colleagues report that retatrutide decreased body weight and improved glycemic control, and that the weight loss was augmented by GCGR-mediated increases in energy expenditure added to the reduction in calorie intake driven by GIPR and GLP-1R (Coskun et al., 2022). The paper’s mouse work uses the same logic as Finan’s, comparing the triple agonist with matched single- and dual-receptor tools to isolate what each receptor contributes. Specific percentage weight loss, a pair-feeding split between intake and expenditure, and hepatic gene-expression fold changes are not stated in the abstract, and figures of that kind circulating in secondary sources should be checked against the paper before they are repeated.

The phase 1 component of the same report established the pharmacokinetic case for weekly administration in humans and recorded that a reduction in body weight persisted to day 43 after a single administration. The subsequent phase 1b study in people with type 2 diabetes, run over 12 weeks with five ascending cohorts, found dose-proportional pharmacokinetics, a half-life of approximately 6 days, and significant placebo-adjusted reductions in mean daily plasma glucose at the three highest exposure levels, with gastrointestinal events the most common adverse events (Urva et al., Lancet, 2022, 400:1869-1881).

Phase 2 Clinical Trial Data

The phase 2 obesity trial (NCT04881760) randomized 338 adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, to placebo or to one of several once-weekly retatrutide regimens for 48 weeks. The primary end point was the percentage change in body weight at 24 weeks. At 24 weeks the least-squares mean change ranged from -7.2 percent in the lowest group to -17.5 percent in the highest, against -1.6 percent for placebo. At 48 weeks the corresponding values were -8.7, -17.1, -22.8 and -24.2 percent for the four ascending maintenance groups, against -2.1 percent for placebo. In the highest group, 100 percent of participants lost at least 5 percent of body weight, 93 percent lost at least 10 percent and 83 percent lost at least 15 percent, compared with 27, 9 and 2 percent on placebo. Adverse events were predominantly gastrointestinal, dose-dependent and mostly mild to moderate, and were partly mitigated by a lower starting exposure. Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter (Jastreboff et al., 2023).

A parallel phase 2 trial in type 2 diabetes (NCT04867785) randomized 281 participants across 42 US centres to placebo, dulaglutide or one of six retatrutide regimens, with change in HbA1c at 24 weeks as the primary end point. HbA1c fell by 0.43 percentage points in the lowest retatrutide group and by 1.30 to 2.02 points in the others, against 0.01 for placebo and 1.41 for dulaglutide, and two of the higher retatrutide groups were significantly better than dulaglutide. Body weight at 36 weeks fell dose-dependently by 3.19 percent in the lowest group up to 16.94 percent in the highest, against 3.00 percent with placebo and 2.02 percent with dulaglutide. Mild to moderate gastrointestinal events occurred in 35 percent of retatrutide-treated participants, there was no severe hypoglycaemia, and there were no deaths (Rosenstock et al., Lancet, 2023, 402:529-544).

Liver Fat Substudy

A substudy of the obesity trial enrolled 98 participants with metabolic dysfunction-associated steatotic liver disease and at least 10 percent liver fat by MRI-PDFF. At 24 weeks the mean relative change in liver fat was -42.9, -57.0, -81.4 and -82.4 percent across the four ascending retatrutide groups, against +0.3 percent for placebo, all significant. Normal liver fat, defined as below 5 percent, was reached by 27, 52, 79 and 86 percent of participants in those groups and by none on placebo. Liver fat reductions tracked changes in body weight, abdominal fat and markers of insulin sensitivity and lipid metabolism (Sanyal et al., Nature Medicine, 2024, 30:2037-2048). An earlier version of this article attributed liver fat figures to a “TRIUMPH-3” presentation; TRIUMPH-3 is a separate phase 3 obesity study, and the liver fat data belong to the Sanyal substudy above.

Comparison With Dual Agonist Research Peptides

The natural comparator is tirzepatide. In SURMOUNT-1, 2539 adults with obesity and without diabetes received placebo or one of three once-weekly tirzepatide regimens for 72 weeks. Under the treatment-regimen estimand, the mean weight change at 72 weeks was -15.0, -19.5 and -20.9 percent for the three ascending groups against -3.1 percent for placebo, and 57 percent of the highest group lost 20 percent or more of body weight (Jastreboff et al., New England Journal of Medicine, 2022, 387:205-216). Retatrutide’s -24.2 percent at 48 weeks is a larger number over a shorter period, but the two trials differ in size, duration, population, escalation schedule and estimand, and no head-to-head trial has been published, so the comparison is indicative rather than a ranking. The semaglutide versus tirzepatide comparison and the tirzepatide versus retatrutide comparison cover the receptor-level differences, and the GLP-1 receptor agonist pharmacology overview places all three in the wider class.

What the Literature Does Not Yet Provide

Several things a reader might expect are not in the published record. There is no published head-to-head trial of retatrutide against tirzepatide or semaglutide. The receptor potency values for retatrutide are reported in the discovery paper’s figures, not as a simple table, and secondary sources that quote precise nanomolar EC50 values with replicate counts should be checked against the paper itself. The phase 2 trials report body weight, HbA1c, liver fat and safety; lipid and inflammatory biomarker changes appear in secondary analyses and supplements rather than in the primary abstracts, and this article no longer quotes figures for them. Phase 3 results from the TRIUMPH programme had not been published in a peer-reviewed journal at the time of writing.

Research Summary

Retatrutide is a GIP-based, fatty-diacid-acylated 39-residue peptide with balanced GCGR and GLP-1R activity and higher GIPR activity in vitro. In obese mice its weight loss exceeds what intake reduction alone explains because GCGR agonism adds energy expenditure, the mechanism first demonstrated for glucagon and GLP-1 co-agonists by Day and Pocai in 2009 and for a balanced triagonist by Finan in 2015. In humans the half-life is about 6 days, weight loss persisted for six weeks after a single administration in phase 1, and the phase 2 programme recorded a 24.2 percent mean weight reduction at 48 weeks in obesity, HbA1c reductions of up to 2.02 percentage points in type 2 diabetes, and liver fat reductions above 80 percent in the two highest groups of the steatotic liver disease substudy. Gastrointestinal adverse events and a transient heart rate increase are the recurring safety signals.

Research Peptide Supply and Verification

For researchers sourcing peptides for in vitro and preclinical studies, purity verification remains the first question. Understanding how to read a Certificate of Analysis is essential when evaluating any research peptide supplier. Maple Research Labs publishes independent third-party certificates of analysis for tested batches, including research-grade retatrutide, and reports the measured purity of each tested batch rather than a blanket figure. Supporting analytical documentation and the full research catalog are available on site. A long acylated sequence such as retatrutide also brings handling considerations of its own, covered in the storage and handling post.

Canadian researchers who previously sourced from US suppliers may find our guide to domestic Canadian peptide sourcing useful, and sourcing considerations specific to this compound are covered in the Canadian retatrutide research sourcing guide. Researchers comparing mechanisms across the metabolic peptide space may also find useful background in our reviews of Adipotide and prohibitin-targeting mechanisms and setmelanotide MC4R agonist pharmacology.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

For peer-reviewed research on this topic, visit PubMed.